517 related articles for article (PubMed ID: 26670477)
21. [Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept].
Schwarzbach M; Lehnert T; Willeke F; Hinz U; Herfarth C
Chirurg; 1996 Dec; 67(12):1237-43. PubMed ID: 9081786
[TBL] [Abstract][Full Text] [Related]
22. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?
Bonvalot S; Laplanche A; Lejeune F; Stoeckle E; Le Péchoux C; Vanel D; Terrier P; Lumbroso J; Ricard M; Antoni G; Cavalcanti A; Robert C; Lassau N; Blay JY; Le Cesne A
Ann Oncol; 2005 Jul; 16(7):1061-8. PubMed ID: 15930042
[TBL] [Abstract][Full Text] [Related]
23. Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients.
Stein U; Jürchott K; Schläfke M; Hohenberger P
J Clin Oncol; 2002 Aug; 20(15):3282-92. PubMed ID: 12149303
[TBL] [Abstract][Full Text] [Related]
24. [Isolated limb perfusion for liposarcoma : Histopathological response and subgroup analysis after TNF melphalan-based ILP].
Podleska LE; Schwindenhammer B; Grabellus F; Bauer S; Steinau HU; Taeger G
Chirurg; 2017 May; 88(5):429-436. PubMed ID: 28083602
[TBL] [Abstract][Full Text] [Related]
25. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
[TBL] [Abstract][Full Text] [Related]
26. Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities.
Boere T; Huis In 't Veld EA; Deroose JP; van Ginhoven TM; Wouters MWJM; Grünhagen DJ; Verhoef C; van Houdt WJ
Eur J Surg Oncol; 2020 Jul; 46(7):1315-1319. PubMed ID: 32359920
[TBL] [Abstract][Full Text] [Related]
27. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185
[TBL] [Abstract][Full Text] [Related]
28. Lower limb function and quality of life after ILP for soft-tissue sarcoma.
Podleska LE; Kaya N; Farzaliyev F; Pöttgen C; Bauer S; Taeger G
World J Surg Oncol; 2017 Apr; 15(1):84. PubMed ID: 28403880
[TBL] [Abstract][Full Text] [Related]
29. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
[TBL] [Abstract][Full Text] [Related]
30. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis.
Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ
Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience.
Assi T; Cavalcanti A; Le Cesne A; Faron M; Honart JF; Hadiji A; Camuzard O; Ibrahim T; LePéchoux C; Mir O; Dumont S; Terrier P; Adam J; Honoré C
Clin Transl Oncol; 2019 Sep; 21(9):1135-1141. PubMed ID: 30656606
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences.
Grabellus F; Kraft C; Sheu SY; Ebeling P; Bauer S; Lendemans S; Schmid KW; Taeger G
Ann Surg Oncol; 2009 Mar; 16(3):676-86. PubMed ID: 19130134
[TBL] [Abstract][Full Text] [Related]
33. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
[TBL] [Abstract][Full Text] [Related]
34. Oncological outcome after hyperthermic isolated limb perfusion for primarily unresectable versus locally recurrent soft tissue sarcoma of extremities.
Vassos N; Brunner M; Perrakis A; Göhl J; Grützmann R; Hohenberger W; Croner RS
Surg Oncol; 2020 Dec; 35():162-168. PubMed ID: 32882523
[TBL] [Abstract][Full Text] [Related]
35. [Limb perfusion in soft tissue sarcomas: twenty years of experience].
Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Pras EB; Suurmeijer A; Hoekstra HJ
Ned Tijdschr Geneeskd; 2013; 157(30):A6148. PubMed ID: 23890169
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
[TBL] [Abstract][Full Text] [Related]
37. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
van Ginkel RJ; Thijssens KM; Pras E; van der Graaf WT; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2007 Apr; 14(4):1499-506. PubMed ID: 17253101
[TBL] [Abstract][Full Text] [Related]
38. 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors.
Kettelhack C; Wickede Mv; Vogl T; Schneider U; Hohenberger P
Cancer; 2002 Mar; 94(5):1557-64. PubMed ID: 11920514
[TBL] [Abstract][Full Text] [Related]
39. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
40. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
